Aadi Bioscience (NASDAQ:AADI – Get Free Report) and BioLineRx (NASDAQ:BLRX – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, analyst recommendations, earnings, risk and institutional ownership.
Profitability
This table compares Aadi Bioscience and BioLineRx’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aadi Bioscience | -246.06% | -71.87% | -57.28% |
| BioLineRx | -90.57% | -163.37% | -34.21% |
Institutional and Insider Ownership
52.1% of Aadi Bioscience shares are held by institutional investors. Comparatively, 1.6% of BioLineRx shares are held by institutional investors. 37.3% of Aadi Bioscience shares are held by insiders. Comparatively, 1.1% of BioLineRx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aadi Bioscience | $25.07 million | 1.67 | -$65.76 million | ($2.35) | -0.72 |
| BioLineRx | $21.99 million | 0.47 | -$60.61 million | ($8.80) | -0.35 |
BioLineRx has lower revenue, but higher earnings than Aadi Bioscience. Aadi Bioscience is trading at a lower price-to-earnings ratio than BioLineRx, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Aadi Bioscience has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500. Comparatively, BioLineRx has a beta of 1.39, meaning that its stock price is 39% more volatile than the S&P 500.
Analyst Ratings
This is a summary of recent ratings for Aadi Bioscience and BioLineRx, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aadi Bioscience | 0 | 5 | 0 | 0 | 2.00 |
| BioLineRx | 0 | 1 | 1 | 0 | 2.50 |
Aadi Bioscience presently has a consensus price target of $1.67, suggesting a potential downside of 1.96%. BioLineRx has a consensus price target of $26.00, suggesting a potential upside of 738.71%. Given BioLineRx’s stronger consensus rating and higher probable upside, analysts clearly believe BioLineRx is more favorable than Aadi Bioscience.
Summary
BioLineRx beats Aadi Bioscience on 8 of the 14 factors compared between the two stocks.
About Aadi Bioscience
Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.
About BioLineRx
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Receive News & Ratings for Aadi Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aadi Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
